For example, treatment of HPV-driven tumors with HPV E7 oncoprotein-derived peptide vaccines combined with TLR3 or TLR9 ligands showed T-cell activation and subsequent tumor regression in vivo [119]. Here, TLR9 is linked to neoplasm.